Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

7,341 total articles

Hims & Hers CFO Conducts Mid-April Share Sales and Exercises Options

Hims & Hers CFO Conducts Mid-April Share Sales and Exercises Options

Hims & Hers Health, Inc. Chief Financial Officer Okupe Oluyemi sold 54,927 shares of Class A common stock across two transactions in mid-April, generating about $1.46 million. The trades were executed under a Rule 10b5-1 plan adopted on May 21, 2025. Mr. Oluyemi also exercised options for 6,184 shares and retains significant direct, indirect an…

Orthofix CLO Executes Sell-to-Cover Transaction, Retains Majority Stake; Company Posts Mixed Quarterly Results

Orthofix CLO Executes Sell-to-Cover Transaction, Retains Majority Stake; Company Posts Mixed Quarterly Results

Jorge Andres Cedron, Chief Legal Officer of Orthofix Medical Inc. (NASDAQ:OFIX), sold 3,743 shares on April 16, 2026 for $47,985 at $12.82 per share to meet tax withholding obligations related to restricted stock unit settlement. The sale was carried out under a pre-authorized sell-to-cover program approved by the Compensation and Talent Developmen…

Cognition Therapeutics CMO Purchases $11,100 of Company Stock

Cognition Therapeutics CMO Purchases $11,100 of Company Stock

Anthony Caggiano, Chief Medical Officer of Cognition Therapeutics Inc. (NASDAQ: CGTX), bought 10,000 shares on April 16, 2026, paying $1.11 per share for a total of $11,100. The transaction leaves him with 874,906 shares on a direct basis. The purchase comes amid notable share-price momentum and follows the company’s 2025 results, which showed a re…

CG Oncology Director Cuts Stake by $1.14M After Option Exercise

CG Oncology Director Cuts Stake by $1.14M After Option Exercise

James Mulay, a director at CG Oncology, disposed of 15,600 common shares on April 17, 2026, through a pre-arranged Rule 10b5-1 plan. The sale, executed at a weighted average price of $73.01, generated proceeds of $1,138,956. Mulay had earlier acquired the same shares by exercising vested director stock options at $36.63 per share. The transaction l…

EyePoint CMO Exercises Options, Sells 2,437 Shares for $36,555

EyePoint CMO Exercises Options, Sells 2,437 Shares for $36,555

EyePoint Chief Medical Officer Ramiro Ribeiro exercised 2,437 stock options and sold the same number of shares on April 17, 2026, generating $36,555 in proceeds. The sale, completed under a Rule 10b5-1 plan, follows a year of strong stock performance even as the company reported a steep revenue decline in Q4 2025 and a large full-year net loss. Sev…

Kayne Anderson EVP Increases Stake with $65,950 Stock Purchase

Kayne Anderson EVP Increases Stake with $65,950 Stock Purchase

Harrison James Little, Executive Vice President at Kayne Anderson Energy Infrastructure Fund, Inc. (NYSE: KYN), acquired 5,000 shares on April 17, 2026, at $13.19 per share for a total of $65,950. The fund's shares are trading slightly higher at $13.39 and have produced a 22% total return over the past year. After the transaction, Little directly h…

GlobalFoundries Legal Chief Sells 500 Shares Under 10b5-1 Plan as Company Sees Active Corporate Moves

GlobalFoundries Legal Chief Sells 500 Shares Under 10b5-1 Plan as Company Sees Active Corporate Moves

Azar Samak L, GlobalFoundries' Chief Legal Officer, sold 500 ordinary shares on April 16, 2026 under a pre-established Rule 10b5-1 plan, realizing $24,355. The transaction leaves her with 17,494 shares. The sale falls within an exemption to a lock-up agreement that expires May 10, 2026. The semiconductor maker is also navigating patent litigation, …

AeroVironment Director Executes $49,322 Share Sale Under 10b5-1 Plan

AeroVironment Director Executes $49,322 Share Sale Under 10b5-1 Plan

Stephen F. Page, a member of AeroVironment Inc.'s board, sold 250 shares of the company on April 15, 2026, for $197.29 per share, a transaction that amounted to roughly $49,322 and was carried out through his living trust under a Rule 10b5-1 trading plan. The trust and Page retain significant remaining positions, while the stock trades well below i…